Bayer, Hitachi, Samsung, Sony and Unilever participated in a series C round for the healthcare monitoring technology provider valuing it near to $1bn.
Huma Therapeutics, a UK-based developer of remote patient monitoring technology, closed a series C round co-led by subsidiaries of chemical and pharmaceutical producer Bayer and electronics manufacturer Hitachi sized at approximately $130m yesterday.
Leaps by Bayer and Hitachi Ventures were joined by electronics providers Samsung and Sony as well as consumer goods producer Unilever, which invested through Samsung Next, Sony Innovation Fund by IGV and Unilever Ventures respectively.
Asset manager HAT’s Technology & Innovation Fund also took part in the…
